Clinical trial for people with house-dust mite allergies

Researchers based in the UK are looking to recruit at least 60 people with asthma and house-dust mite allergy to take part in a clinical trial.

Clinical trials are carried out to try and find new or better ways of preventing, diagnosing, monitoring or treating and managing the symptoms of a variety of health conditions, including asthma.

The aim of this particular clinical trial, known as the MITRA study, is to test the effectiveness of a house-dust mite allergy vaccine tablet (taken once daily) compared to placebo in people with house-dust mite induced asthma.

This will be tested by measuring whether, in those people who take the tablet, there is a reduction in the risk for worsening asthma symptoms, which could potentially lead to an asthma attack.

The lead researcher for this project is Professor Stephen Durham who works at the MRC-Asthma UK Centre in Allergic Mechanisms of Asthma and has previously been funded by Asthma UK to carry out other research studies to help improve our understanding of asthma and related allergies.

Professor Durham, Head of Section for Allergy and Clinical Immunology at the National Heart and Lung Institute, Imperial College says:'House-dust mite allergy is a major problem for many people with asthma. The aim of the MITRA study is to treat the underlying cause and prevent the worsening of asthma symptoms in this vulnerable group rather than just treat symptoms. If you have asthma and a major trigger for your asthma is in response to dusting, vacuuming and/or bed making in the home then you may be eligible to take part'.

The trial is sponsored by ALK-Abelló A/S (in short ALK), which is a global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. More information about the study can be found at the website Information about taking part in clinical trials can be found on the UK Clinical Research Centre web page at the following link:


(Original article)

Previous Stories